Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.
The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.
Caribou Biosciences (Nasdaq: CRBU), società biofarmaceutica in fase clinica specializzata nell'editing genomico CRISPR, ha annunciato la sua partecipazione alla conferenza Citi 2025 Biopharma Back to School. Rachel Haurwitz, PhD, presidente e CEO dell'azienda, prenderà parte a un fireside chat il 3 settembre 2025 alle 14:30 EDT.
La presentazione sarà trasmessa in webcast dalla pagina Eventi del sito web di Caribou e resterà disponibile per almeno 30 giorni dopo l'evento.
Caribou Biosciences (Nasdaq: CRBU), una empresa biofarmacéutica en fase clínica centrada en la edición genómica CRISPR, anunció su participación en la conferencia Citi 2025 Biopharma Back to School. Rachel Haurwitz, PhD, presidenta y directora ejecutiva de la compañía, participará en un fireside chat el 3 de septiembre de 2025 a las 14:30 EDT.
La presentación se podrá ver por webcast en la página de Eventos del sitio web de Caribou y permanecerá disponible durante al menos 30 días después del evento.
Caribou Biosciences (Nasdaq: CRBU), 임상 단계의 CRISPR 유전체 편집 바이오제약사인 카리부 바이오사이언시스는 다가오는 Citi 2025 Biopharma Back to School 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Rachel Haurwitz, PhD가 2025년 9월 3일 오후 2시 30분(EDT)에 파이어사이드 챗에 참석합니다.
발표는 카리부 웹사이트의 이벤트 페이지에서 웹캐스트로 시청할 수 있으며 행사 후 최소 30일간 다시보기로 제공됩니다.
Caribou Biosciences (Nasdaq: CRBU), une société biopharmaceutique en phase clinique spécialisée dans l'édition génomique CRISPR, a annoncé sa participation à la conférence Citi 2025 Biopharma Back to School. Rachel Haurwitz, PhD, présidente et PDG de l'entreprise, participera à un fireside chat le 3 septembre 2025 à 14h30 EDT.
La présentation sera accessible via un webcast sur la page Événements du site web de Caribou et restera disponible pendant au moins 30 jours après l'événement.
Caribou Biosciences (Nasdaq: CRBU), ein klinisch tätiges Biopharmaunternehmen im Bereich CRISPR-Genomeditierung, hat seine Teilnahme an der Citi 2025 Biopharma Back to School Conference angekündigt. Rachel Haurwitz, PhD, Präsidentin und CEO des Unternehmens, wird am 3. September 2025 um 14:30 Uhr EDT an einem Fireside Chat teilnehmen.
Die Präsentation wird per Webcast auf der Veranstaltungsseite von Caribous Website übertragen und ist mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT.
For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com
